Key Takeaway
The next chapter in weight loss medication is being written right now. CagriSema Novo Nordisk's investigational drug combines two hormones) semaglutide (a GLP-1 receptor agonist) and cagrilintide (a long-acting amylin analog), into a single weekly injection.
Short answer
CagriSema is best understood by pairing the current status snapshot with the strongest named evidence source. That keeps the page useful for search, AI answers, and real readers who need to know what is proven, what is plausible, and what is still unsettled.
CagriSema status snapshot (reviewed April 27, 2026)
| Developer | Novo Nordisk |
| Mechanism | Fixed-dose cagrilintide plus semaglutide; amylin analogue plus GLP-1 receptor agonist biology. |
| Route | Once-weekly subcutaneous injection in phase 3 obesity studies. |
| U.S. status | Submitted to the FDA in December 2025; not FDA approved for chronic weight management as of April 27, 2026. |
| Global status | Regulatory review and additional phase 3/phase 3b studies. |
| Evidence to read first | REDEFINE 1 and REDEFINE 2 are the core obesity and obesity-with-type-2-diabetes studies. |
| Practical limit | The data are strong, but approval, label language, price, supply, and real-world adherence are still decisive. |
This page was upgraded to make the answer usable for traditional search, AI summaries, and human readers: status first, evidence second, and speculation clearly labeled.
The next chapter in weight loss medication is being written right now. CagriSema Novo Nordisk's investigational drug combines two hormones) semaglutide (a GLP-1 receptor agonist) and cagrilintide (a long-acting amylin analog), into a single weekly injection. In clinical trials, this combination has produced up to 25 percent body weight loss, making it the most effective obesity medication ever studied.
Key Takeaways: - Understand what is CagriSema and how does it work - Clinical Trial Results: What the Data Shows - Side Effects and Safety Profile - Timeline, Availability, and What to Watch For
Here is what you need to know about CagriSema, how it works, what the trial data shows, and when it might become available.
What Is CagriSema and How Does It Work?
CagriSema is a fixed-ratio combination of two active compounds.
Semaglutide is the GLP-1 receptor agonist you may already know from weight management and diabetes treatment. It works by mimicking the GLP-1 hormone your gut releases after eating. This slows gastric emptying, increases insulin release, reduces glucagon, and acts on brain regions that control appetite and satiety. Semaglutide alone has shown about 15 to 17 percent average body weight loss in clinical trials.
Cagrilintide is a long-acting analog of amylin, a hormone released by the pancreas alongside insulin after meals. Amylin has several effects that complement GLP-1. It slows gastric emptying through a different pathway, reduces post-meal glucagon release, and acts on the area postrema and other brainstem regions to promote fullness.
The key insight behind CagriSema is that GLP-1 and amylin regulate appetite through different but complementary brain circuits. By activating both pathways at once, the combination produces stronger appetite suppression and greater weight loss than either hormone alone.
Think of it this way (semaglutide turns down the hunger signal through one set of pathways. Cagrilintide turns it down through a different set. Together, they reduce appetite more than either could independently.
"Compounding pharmacies serve a critical role in healthcare, but patients need to understand the difference between a properly regulated 503B facility and an unregulated operation. Ask about PCAB accreditation and third-party testing.") Dr. Scott Brunner, PharmD, Alliance for Pharmacy Compounding
For background on how GLP-1 medications work, see our .
Clinical Trial Results: What the Data Shows
The REDEFINE clinical trial program is testing CagriSema across multiple patient populations. The results so far have generated significant attention.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Tirzepatide | 22 | ~22% body weight at 72 wks |
| Semaglutide | 15 | ~15% body weight at 68 wks |
| Liraglutide | 8 | ~8% body weight at 56 wks |
| Retatrutide | 24 | ~24% in Phase 2 trial |
Free Download: GLP-1 Medication Comparison One-Pager Compare GLP-1 medications side by side (active ingredients, dosing schedules, and key differences. Get yours free) we'll email it to you instantly. [Download Now]
REDEFINE 1 was the key phase 3 trial in adults with obesity or overweight with at least one weight-related complication. After 68 weeks of treatment:
- CagriSema produced an average body weight loss of approximately 22 to 25 percent.
- Semaglutide alone (2.4 mg) produced about 16 percent weight loss in the comparator arm.
- Cagrilintide alone produced about 8 percent weight loss.
- The combination clearly outperformed either component on its own.
To put those numbers in context, a person weighing 250 pounds could expect to lose roughly 55 to 62 pounds on CagriSema over about 16 months. That level of weight loss approaches what is typically seen only with bariatric surgery.
REDEFINE 2 studied CagriSema in people with type 2 diabetes and obesity. The results showed strong A1C reductions alongside significant weight loss, suggesting the drug could address both conditions simultaneously.
How CagriSema compares to tirzepatide. No direct head-to-head trial between CagriSema and tirzepatide has been conducted. Tirzepatide (which combines GLP-1 and GIP receptor activation) has shown about 20 to 22 percent weight loss in its trials. CagriSema's numbers appear modestly higher, but differences in trial populations and design make direct comparison imperfect. For more on how current GLP-1 options compare, see our .
Side Effects and Safety Profile
CagriSema's side effect profile is broadly similar to other GLP-1 medications, though the combination does bring some nuances.
Gastrointestinal side effects remain the most common issue. Nausea, vomiting, diarrhea, and constipation were reported by a significant percentage of trial participants. Because both semaglutide and cagrilintide slow gastric emptying, the GI effects can be more pronounced than with semaglutide alone (at least during the initial dose escalation period.
Dose titration helps. CagriSema uses a slow dose escalation schedule specifically designed to reduce GI side effects. Most participants in the trials reported that nausea was worst in the first four to eight weeks and improved substantially after that.
Injection site reactions were reported at slightly higher rates than semaglutide alone, possibly because the injection volume is larger when combining two compounds. These were generally mild) redness, itching, or minor swelling at the injection site.
Discontinuation rates due to side effects were modestly higher than semaglutide alone in some trial arms, but the majority of participants completed the full treatment period. The very strong weight loss results likely motivated many participants to push through early side effects.
Serious adverse events including pancreatitis and gallbladder issues occurred at similar rates to other GLP-1 medications. The overall safety profile hasn't raised any new red flags specific to the amylin component.
For tips on managing GI side effects with GLP-1 medications, read our .
Ready to explore GLP-1 treatment options available now? .
Timeline, Availability, and What to Watch For
CagriSema isn't yet available. Here is what we know about its path to market.
Regulatory submissions. Novo Nordisk has submitted CagriSema for FDA approval based on the REDEFINE program data. The FDA review process typically takes 10 to 12 months from submission. An approval decision could come in late 2026 or early 2027.
Manufacturing challenges. One reason Novo Nordisk is pursuing CagriSema aggressively is market positioning. They're investing billions in manufacturing capacity to avoid the supply shortages that plagued semaglutide during its rapid growth period. But initial supply at launch may still be limited.
Insurance and cost. Pricing hasn't been announced, but CagriSema will likely be positioned as a premium product. Given the stronger weight loss results, some insurers may cover it for patients who haven't achieved adequate results with existing GLP-1 monotherapy.
What you can do now. CagriSema isn't available yet, but effective GLP-1 treatment options exist today. Compounded semaglutide and tirzepatide are available through licensed providers and 503A pharmacies. If weight management is your goal, there's no reason to wait (you can start building healthy habits and making progress now, and transition to newer medications if and when they become available.
Stay realistic about expectations. Clinical trial results represent averages. Some participants lost more than 25 percent of their body weight, and some lost less. Individual results depend on genetics, adherence, diet, exercise, and many other factors. No medication guarantees a specific outcome.
To see if you qualify for GLP-1 treatment available today, .
Frequently Asked Questions
When will CagriSema be available?
CagriSema is currently under FDA review. If approved, it could become available in late 2026 or early 2027. But initial supply may be limited. Your provider can help you stay informed about availability as the launch approaches.
How is CagriSema different from tirzepatide?
CagriSema combines semaglutide (GLP-1) with cagrilintide (amylin analog), while tirzepatide combines GLP-1 with GIP receptor activation. They use different hormone combinations to enhance weight loss beyond what GLP-1 alone can achieve. No direct head-to-head trial has compared them, but CagriSema's phase 3 data suggests slightly higher average weight loss.
Will CagriSema replace semaglutide?
Not necessarily. Semaglutide remains an effective treatment for many people and may be preferred when side effect tolerance, cost, or insurance coverage are factors. CagriSema is likely to be positioned as an option for patients who need more aggressive weight management than semaglutide alone can provide.
Can I take CagriSema if I am already on semaglutide?
CagriSema already contains semaglutide, so you wouldn't take both simultaneously. If CagriSema becomes available and your provider recommends it, you would transition from semaglutide monotherapy to the combination product. Your provider would manage the dosing transition.
What is amylin and why does adding it help with weight loss?
Amylin is a hormone your pancreas releases alongside insulin after meals. It slows digestion, reduces post-meal blood sugar spikes, and sends satiety signals to the brain through pathways different from GLP-1. By activating both the GLP-1 and amylin pathways, CagriSema suppresses appetite more effectively than targeting either pathway alone.
Ready to Take the Next Step?
Your health outcomes is personal) and you deserve a plan that fits. FormBlends connects you with licensed providers who can evaluate your needs and create a personalized protocol.
Medical References
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. [PubMed | ClinicalTrials.gov | DOI]
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021;325(14):1403-1413. [PubMed | ClinicalTrials.gov | DOI]
- Garvey WT, Batterham RL, Bhatt DL, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med. 2022;28(10):2083-2091. [PubMed | ClinicalTrials.gov | DOI]
- Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626. [PubMed | ClinicalTrials.gov | DOI]
- Wadden TA, Chao AM, Engel S, et al. Tirzepatide with intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3). Nat Med. 2024. [PubMed | ClinicalTrials.gov | DOI]
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48. [PubMed | ClinicalTrials.gov | DOI]
Sources &. References
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. Doi:10.1056/NEJMoa1411892
- Marso SP, Daniels GH, Tanaka K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. Doi:10.1056/NEJMoa1603827
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Doi:10.1056/NEJMoa2032183
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 (Davies et al., Lancet, 2021)). Lancet. 2021;397(10278):971-984. Doi:10.1016/S0140-6736(21)00213-0
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3 (Wadden et al., JAMA, 2021)). JAMA. 2021;325(14):1403-1413. Doi:10.1001/jama.2021.1831
- Garvey WT, Batterham RL, Bhatt DL, et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5 (Garvey et al., Nat Med, 2022)). Nat Med. 2022;28:2083-2091. Doi:10.1038/s41591-022-02026-4
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. Doi:10.1056/NEJMoa2307563
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. Doi:10.1056/NEJMoa2206038
- Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2[4] (Garvey et al., Lancet, 2023)). Lancet. 2023;402(10402):613-626. Doi:10.1016/S0140-6736(23)01200-X
- Wadden TA, Chao AM, Engel S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3[5] (Wadden et al., Nat Med, 2023)). Nat Med. 2023. Doi:10.1038/s41591-023-02597-w
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4[6] (Aronne et al., JAMA, 2024)). JAMA. 2024;331(1):38-48. Doi:10.1001/jama.2023.24945
- Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391:1193-1205. Doi:10.1056/NEJMoa2404881
This article is for educational purposes only and doesn't constitute medical advice. Always consult with a licensed healthcare provider before starting, changing, or stopping any medication or supplement. FormBlends connects you with licensed providers who can evaluate your individual health needs.
Last updated: 2026-03-24
What changed for CagriSema in 2026
The 2026 job is to separate the December 2025 U.S. filing and phase 3 results from an actual approved product. CagriSema has a credible late-stage evidence base, but routine U.S. prescribing still depends on FDA action and the final label.
For overview pages, that means the page should answer status, evidence, safety, access, and uncertainty in a predictable order.
For the broader evidence map, read the CagriSema complete guide, then compare it with CagriSema clinical trial results: REDEFINE 1, REDEFINE 2, and what the numbers actually mean, CagriSema FDA approval timeline: filed in 2025, still waiting in 2026, and why the delay matters, CagriSema mechanism of action, without the fluff.
Claims we would not make yet
One of the easiest ways to over-optimize a pipeline page is to make it sound more certain than the evidence allows. For CagriSema, we would keep these boundaries explicit:
- Do not call CagriSema FDA approved until an FDA approval and label exist.
- Do not rank it above tirzepatide, semaglutide, or retatrutide as if there were a direct head-to-head tournament.
- Do not turn if-all-adhered trial estimates into guaranteed real-world results.
How to read the evidence without overclaiming
For CagriSema, the strongest answer is not the most dramatic answer. It is the answer that separates what has been shown, what is biologically plausible, and what still needs a label, trial readout, or real-world follow-up.
| Evidence layer | What it means for this page |
|---|---|
| Settled enough to state | Submitted to the FDA in December 2025; not FDA approved for chronic weight management as of April 27, 2026. Fixed-dose cagrilintide plus semaglutide; amylin analogue plus GLP-1 receptor agonist biology. |
| Useful but conditional | Novo reports 22.7% vs 2.3% weight loss in REDEFINE 1 and 15.7% vs 3.1% in REDEFINE 2 in if-all-adhered analyses at 68 weeks. This is useful context, but it still depends on population, duration, estimand, dose, and adherence. |
| Still unknown or changing | Long-term real-world persistence, payer behavior, comparative ranking, market access, and the exact patient groups most likely to benefit. |
Verification checklist for 2026
Before using this page to make a medical, investment, or content decision about CagriSema, verify the moving parts that can change fastest.
- Check status, evidence source, safety, access, and comparison limits in that order.
- Confirm whether the page is written for the United States, China, Europe, or a global pipeline audience.
- Look for the current prescribing information when a product is approved; for investigational products, use the latest trial registry and sponsor update instead.
- Separate access from efficacy. A drug can look strong scientifically and still be unavailable, uncovered, or inappropriate for a specific patient.
Evidence ledger
The strongest version of this topic should cite primary or near-primary sources, not just repeat another SEO page. These are the sources this page should be checked against first:
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →
